Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Bolt Biotherapeutics (BOLT) Net Margin (2020 - 2025)

Bolt Biotherapeutics' Net Margin history spans 6 years, with the latest figure at 333.15% for Q3 2025.

  • For Q3 2025, Net Margin rose 99691.0% year-over-year to 333.15%; the TTM value through Sep 2025 reached 824.54%, down 11118.0%, while the annual FY2024 figure was 881.57%, 299.0% down from the prior year.
  • Net Margin for Q3 2025 was 333.15% at Bolt Biotherapeutics, up from 477.33% in the prior quarter.
  • Across five years, Net Margin topped out at 293.63% in Q1 2024 and bottomed at 5345.87% in Q4 2021.
  • The 5-year median for Net Margin is 1145.17% (2023), against an average of 1496.81%.
  • The largest annual shift saw Net Margin surged 392864bps in 2022 before it crashed -68698bps in 2024.
  • A 5-year view of Net Margin shows it stood at 5345.87% in 2021, then surged by 73bps to 1417.22% in 2022, then surged by 40bps to 857.01% in 2023, then plummeted by -55bps to 1330.06% in 2024, then surged by 75bps to 333.15% in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Net Margin are 333.15% (Q3 2025), 477.33% (Q2 2025), and 905.24% (Q1 2025).